Endothelial cell expression of mutant Map2k1 causes vascular malformations in mice
Extracranial arteriovenous malformation (AVM) is a congenital vascular anomaly causing disfigurement, bleeding, ulceration, and pain. Most lesions are associated with somatic MAP2K1 activating mutations in endothelial cells (ECs). The purpose of this study was to determine if EC expression of mutant...
Gespeichert in:
Veröffentlicht in: | Angiogenesis (London) 2023-02, Vol.26 (1), p.97-105 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Extracranial arteriovenous malformation (AVM) is a congenital vascular anomaly causing disfigurement, bleeding, ulceration, and pain. Most lesions are associated with somatic MAP2K1 activating mutations in endothelial cells (ECs). The purpose of this study was to determine if EC expression of mutant activated MAP2K1 is sufficient to produce vascular malformations in mice. We generated mice with a
ROSA26
allele containing a lox-stop-lox gene trap (GT),
Map2k1
cDNA with an activating p.K57N missense mutation, an internal ribosomal entry site, and green fluorescent protein cDNA (
R26
GT−Map2k1−GFP
). We expressed mutant MAP2K1 and GFP in ECs of fetal and newborn mice using
Tg-Cdh5Cre
or
Tg-Cdh5CreER
alleles.
Tg-Cdh5Cre
+/−
;R26
GT−Map2k1−GFP/
+
animals that express mutant MAP2K1 in ECs in utero developed diffuse vascular abnormalities and died by embryonic (E) day 16.5.
Tg-Cdh5CreER
+/−
;R26
GT−Map2k1−GFP/
+
animals in which mutant MAP2K1 expression was induced in ECs by tamoxifen at postnatal (P) day 1 developed vascular malformations in the brain, ear, and intestines by P23. The lesions consisted of abnormal networks of blood vessels containing recombined and non-recombined ECs. In conclusion, expression of MAP2K1 p.K57N is sufficient to cause vascular malformations in mice. This model can be used to study the malformation process and for pre-clinical pharmacologic studies. |
---|---|
ISSN: | 0969-6970 1573-7209 |
DOI: | 10.1007/s10456-022-09853-6 |